Literature DB >> 26496934

Why the drug development pipeline is not delivering better medicines.

Huseyin Naci1, Alexander W Carter2, Elias Mossialos3.   

Abstract

Mesh：

Year:  2015        PMID： 26496934     DOI： 10.1136/bmj.h5542

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Measuring the efficiency of large pharmaceutical companies: an industry analysis.

Authors:  Fernando Gascón; Jesús Lozano; Borja Ponte; David de la Fuente
Journal:  Eur J Health Econ       Date:  2016-06-25

Review 2.  Molecular Imaging in Drug Discovery and Development.

Authors:  Jonathan R Lindner; Jeanne Link
Journal:  Circ Cardiovasc Imaging       Date:  2018-02       Impact factor: 7.792

Review 3.  [The problem of medical overuse : Finding a definition and solutions].

Authors:  T Gamstätter
Journal:  Internist (Berl)       Date:  2021-02-13       Impact factor: 0.743

4.  The proportion of North American cancer trials that evaluate novel targets.

Authors:  Eli Gumnit; Aden C Feustel; Sandy Wong; Rafia Bosan; Nora Hutchinson; Jonathan Kimmelman
Journal:  Invest New Drugs       Date:  2020-07-18       Impact factor: 3.850

5.  The DIY Digital Medical Centre.

Authors:  James Kenneth Timmis; Kenneth Timmis
Journal:  Microb Biotechnol       Date:  2017-08-25       Impact factor: 5.813

6.  Current Problems in the Research and Development of more Effective Antidepressants.

Authors:  Tianmei Si; Xin Yu
Journal:  Shanghai Arch Psychiatry       Date:  2016-06-25

7.  Innovative regenerative medicines in the EU: a better future in evidence?

Authors:  Mark S Corbett; Andrew Webster; Robert Hawkins; Nerys Woolacott
Journal:  BMC Med       Date:  2017-03-08       Impact factor: 8.775

8.  BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management.

Authors:  Victor G Rodwin; Guilhem Fabre; Rafael F Ayoub
Journal:  Int J Health Policy Manag       Date:  2018-03-01

9.  Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors:  Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal:  BMJ       Date:  2019-09-18

10.  Health and Ethical Consequences of Outsourcing Pivotal Clinical Trials to Latin America: A Cross-Sectional, Descriptive Study.

Authors:  Núria Homedes; Antonio Ugalde
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.